NCT01144299View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

June 17, 2010

Primary Completion Date

July 10, 2010

Study Completion Date

July 10, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix™/Influsplit SSW®

Single intramuscular dose on Day 0

Trial Locations (6)

01067

GSK Investigational Site, Dresden

01069

GSK Investigational Site, Dresden

01097

GSK Investigational Site, Dresden

01099

GSK Investigational Site, Dresden

01129

GSK Investigational Site, Dresden

01705

GSK Investigational Site, Freital

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01144299 - A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter